Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.56M P/E - EPS this Y 38.70% Ern Qtrly Grth -
Income -8.56M Forward P/E -2.88 EPS next Y 74.90% 50D Avg Chg -8.00%
Sales 428k PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book 8.03 EPS next 5Y - 52W High Chg -25.00%
Recommedations 2.00 Quick Ratio 0.35 Shares Outstanding 3.50M 52W Low Chg 78.00%
Insider Own 18.06% ROA -115.93% Shares Float 1.62M Beta 1.26
Inst Own 2.47% ROE - Shares Shorted/Prior 151.24K/64.85K Price 1.96
Gross Margin - Profit Margin - Avg. Volume 25,955 Target Price 25.00
Oper. Margin -54,966.67% Earnings Date Nov 6 Volume 11,925 Change -2.49%
About BioCardia, Inc.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

BioCardia, Inc. News
11/16/24 BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)
11/14/24 BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...
11/13/24 BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
11/06/24 BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
10/28/24 BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
10/09/24 BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
09/18/24 BioCardia Regains Full Compliance with Nasdaq Listing Requirements
09/09/24 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
08/30/24 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
08/29/24 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
06:00 AM FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
08/13/24 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
08/07/24 BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
07/30/24 BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
07/25/24 Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
07/17/24 BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
07/08/24 CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
06/07/24 BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
04:00 PM BioCardia Announces Reverse Stock Split
05/15/24 BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...
BCDA Chatroom

User Image CEOBuysDisclosures Posted - 2 days ago

$BCDA CEO purchased 1,350 shares at $1.87 for a total of $2,525. Altman Peter now owns 105,331 shares. https://ceo-buys.com

User Image Stokedemarket Posted - 2 days ago

$BCDA JFK junior pump?

User Image canievas Posted - 2 days ago

$BCDA adding more here 🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀

User Image GJ_Rockabilt Posted - 2 days ago

$BCDA Not much has changed, since the good News, in my opinion.

User Image PenkeTrading Posted - 5 days ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Biocardia Inc. Is that bullish or bearish? $BCDA #RsiOversold #NASDAQ

User Image Pavlicek Posted - 6 days ago

$BCDA 😳$CERO 🚀🚀🚀

User Image GJ_Rockabilt Posted - 6 days ago

$BCDA it really doesn't matter, whether $BCDA gets bought out, or not. They have the talents to achieve Mid Cap status within. Strengths are Sales too early to realize, yet) and Innovation. I should be Buying Down, for quite a while.

User Image Thestocktraderhubzee Posted - 6 days ago

WATCHLIST NOV 15 2024. $SMPL Citigroup Maintains Buy on Simply Good Foods, Lowers Price Target to $43 $WFRD Citigroup Maintains Buy on Weatherford International, Lowers Price Target to $115 $CHX Citigroup Maintains Buy on ChampionX, Lowers Price Target to $40 $BCDA HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target $BKR Citigroup Maintains Buy on Baker Hughes, Raises Price Target to $50

User Image Wut Posted - 6 days ago

$BCDA still on track for a decent entry after the next reverse split. Should line up better with their catalysts as well. Until then, as before, no real point in holding unless you're hoping for some off the wall buyout before then.

User Image janerik504 Posted - 6 days ago

$BCDA hello darkness, my old friend…..i’ve come to talk with you again

User Image janerik504 Posted - 6 days ago

$BCDA sorry. i caused this as i accidentally bought more yesterday when i looked at my account. i figured it was meant to be….

User Image Penny_Stonk_Scalper Posted - 6 days ago

$BCDA 🤦‍♂️ hope it bounces off the 52 week low. Or holds. Science geeks doing good things to save people but can’t run the business side.

User Image canievas Posted - 6 days ago

$BCDA BUYING MORE. REMEMBER BEFORE THE SQUEEZE SHE DUMPS. HAPPENS ALLL TIME. BUY BUY AND HOLD WHAT IS COMING IS SIMILAR LIKE $DRUG buy now you won’t regret it 🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀

User Image Barbazan Posted - 6 days ago

$BCDA is just a disaster, hopeless

User Image Romerob2 Posted - 6 days ago

$BCDA what’s going on with this pos

User Image GJ_Rockabilt Posted - 1 week ago

$BCDA

User Image GJ_Rockabilt Posted - 1 week ago

$BCDA I've been Buying down, myself.

User Image Penny_Stonk_Scalper Posted - 1 week ago

$BCDA just need Medtronic to buy MorphDNA.

User Image Market_Luther_Kang Posted - 1 week ago

$BCDA Biocardia will be attending scientific sessions at: American Heart Association 2024 Technology and Heart Failure Therapeutics 2025 American College of Cardiology 2025 International Society for Heart and Lung Transplantation 2025

User Image Jusme Posted - 1 week ago

$BCDA I'm not surprised with today's report - as the earlier quarterly was referencing EoQ4 for the most notable milestones, and had predicted this would essentially be a "we're working towards our milestones". One thing that has slipped into the Q1'25 is a partnership,... The potential PMDA approval could be quite significant for an upside,... but there's the business development / partnering timeframe added to this. I'm less bullish now versus a year ago... In football terms, Altman needs to focus on block & tackling to considerably move the company down the field and score a goal.

User Image Market_Luther_Kang Posted - 1 week ago

$BCDA Most interesting news on the call was that Altman is actively seeking to sell the Morph part of the business. Actually a better plan than seeking a partnership. Glad he also clarified the plan in Japan - partnership in lieu of going it alone. Still not happy with the results though. Was hoping for more substance. Altman really is the king of lackluster news.

User Image LeakyWallet Posted - 1 week ago

$BCDA the fact that earnings is tonight and this thing is showing no signs of insider activity buying it up has me kind of concerned that it’s gonna be a dud..?

User Image chris_stocks Posted - 1 week ago

$BCDA Does anyone think the stock will spike tomorrow because of the earnings report?

User Image HuntStockTrader Posted - 1 week ago

$BCDA

User Image investorTim Posted - 1 week ago

$BCDA 👀

User Image GJ_Rockabilt Posted - 1 week ago

$BCDA We are only about 17% off one year Split Adjusted one year low. Make of it what you will. I might try Early Bird method on Value. You?

User Image investorTim Posted - 1 week ago

$BCDA 📈🤞

User Image CliffordCapital Posted - 1 week ago

$BCDA why is the sentiment here so bearish? If P3 is good this could run 100%+ easily.

User Image canievas Posted - 1 week ago

$BCDA IM STILL HERE HOLDING THOUSANDS IF SHARES. IM NOTNIN THE RUSH SELLING. SHE WILL RUN HARD WHEN THE TIME OS RIGHT 🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀💪🏼🚀🚀🚀

User Image investorTim Posted - 1 week ago

$BCDA primmed

Analyst Ratings
HC Wainwright & Co. Buy Aug 21, 24
HC Wainwright & Co. Buy Aug 16, 24
HC Wainwright & Co. Buy Jul 26, 24
HC Wainwright & Co. Buy May 29, 24
HC Wainwright & Co. Buy Nov 14, 23
HC Wainwright & Co. Buy Oct 11, 23
HC Wainwright & Co. Buy Sep 6, 23
HC Wainwright & Co. Buy Aug 10, 23
HC Wainwright & Co. Buy Jul 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
FROST PHILLIP MD ET AL 10% Owner 10% Owner Jan 19 Sell 0.43 129,802 55,815 1,896,025 01/22/24
Altman Peter President and CEO President and CEO Jan 11 Buy 1.87 100 187 353,715 04/14/23
FROST PHILLIP MD ET AL 10% Owner 10% Owner Dec 16 Buy 1.68 595,238 1,000,000 2,025,827 12/20/22